Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease

Blood

Volumn 112, Issue 5, 2008, Pages 1960-1970

  Agarwal, Anupriya ^a,b   Bumm, Thomas G P ^a   Corbin, Amie S ^a,b   O'Hare, Thomas ^a,b   Loriaux, Marc ^a   Van Dyke, Jonathan ^a   Willis, Stephanie G ^a   Deininger, Jutta ^c   Nakayama, Keiichi I ^d   Druker, Brian J ^a,b   Deininger, Michael W ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; FLT3 LIGAND; IMATINIB; JANUS KINASE 2; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PRIMER DNA; PROTEIN TYROSINE KINASE; S PHASE KINASE ASSOCIATED PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CELL CYCLE ARREST; CONTROLLED STUDY; LEUKEMIA; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; ANIMAL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL CYCLE; CHRONIC MYELOID LEUKEMIA; DRUG ANTAGONISM; GENE EXPRESSION; GENETICS; METABOLISM; MOUSE MUTANT; NUCLEOTIDE SEQUENCE; ONCOGENE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; BONE MARROW TRANSPLANTATION; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA PRIMERS; GENE EXPRESSION; GENES, ABL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOPROLIFERATIVE DISORDERS; PROTEIN-TYROSINE KINASES; S-PHASE KINASE-ASSOCIATED PROTEINS;

EID: 52649104330     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-09-113860     Document Type: Article

References (51)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343-3356.
2. Clarkson B, Strife A, Wisniewski D, Lambek CL; Liu C. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia. 2003;17:1211-1262.
3. Attar EC, Scadden DT. Regulation of hematopoietic stem cell growth. Leukemia. 2004;18:1760-1768.
4. Skorski T. Kanakaraj P. Nieborowska-Skorska M, et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood. 1995;86:726-736.
5. Cortez D, Reuther G, Pendergast AM. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene. 1997;15:2333-2342.
6. Shuai K, Halpern J. ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABLoncogene in chronic myelogenous leukemia. Oncogene. 1996;13: 247-254.
7. Li S. Src kinase signaling in leukaemia. Int J Biochem Cell Biol. 2007;39:1483-1488.
8. Raitano AB. Halpern JR. Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun fortransformation. Proc Natl Acad Sci U S A. 1995;92:11746-11750.
9. Jonuleit T, Peschel C, Schwab R, et al. Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors. Br J Haematol. 1998;100:295-303.
10. Jiang Y, Zhao RC, Verfaillie CM. Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BGR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip. which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity. Proc Natl Acad Sci U S A. 2000;97:10538-10543.
11. Kramer A, Horner S, Wilier A, et al. Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells. Proc Natl Acad Sci U S A. 1999;96:2087-2092.
12. Parada Y, Banerji L Glassford J, etal. BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression. J Biol Chem. 2001;276:23572-23580.
13. Jonuleit T van der Kuip H, Miething C, et al. Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood. 2000;96:1933-1939.
14. Andreu EJ, Lledo E, Poch E, etal. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res. 2005;65:3264-3272.
15. Lim MS, Adamson A, Lin Z, et al. Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index. Blood. 2002;100:2950-2956.
16. Gstaiger M, Jordan R, Lim M, et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A. 2001; 98:5043-5048.
17. Yang G, Ayala G, De Marzo A, et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res. 2002; 8:3419-3426.
18. Ma XM, Liu JH, Guo JW, Liu Y, Zuo LF. [Correlation of Skp2 expression in gastric carcinoma to expression of P27 and PTEN]. Ai Zheng. 2006; 25:56-61.
19. Hershko DD, Shapira M. Prognostic role of p27(Kip1) deregulation in colorectal cancer. Cancer. 2006;107:668-675.
20. Latres E, Chiarle R, Schulman BA, et al. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci U S A. 2001;98:2515-2520.
21. La Rosee R Johnson K, O'Dwyer ME, Druker BJ. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol. 2002;30:729-737.
22. Tsutsui M, Shimokawa H, Yoshihara S, et al. Intracellular magnesium deficiency in acute myocardial infarction. Jpn Heart J. 1993;34:391-401.
23. O'Hare T, Pollock R, Stoffregen ER et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood. 2004;104: 2532-2539.
24. Corbin AS, Buchdunger E, Pascal F, Druker BJ. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem. 2002;277:32214-32219.
25. Vallera DA, Jin N, Baldrica JM, Panoskaltsis-Mortari A, Chen SY Blazar BR. Retroviral immunotoxin gene therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin gene. Cancer Res. 2000;60:976-984.
26. Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood. 1998; 92:3829-3840.
27. Million RP, Aster J, Gilliland DG, Van Etten RA. The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood. 2002;99:4568-4577.
28. Roumiantsev S, deAos IE, Varticovski L, Maria RL, Van Etten RA. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood. 2001;97:4-13.
29. Smith KM. Yacobi R, Van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell. 2003;12:27-37.
30. Wernig G, MercherT, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107:4274-4281.
31. Christensen JL, Weissman IL. Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. Proc Natl Acad Sci U S A. 2001;98:14541-14546.
32. Kotani H, Newton PB. 3rd Zhang S, etal. Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther. 1994;5:19-28.
33. Bumm TG, Elsea C, Corbin AS, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res. 2006;66:11156-11165.
34. Hao B, Zheng N, Schulman BA, et al. Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase. Mol Cell. 2005;20:9-19.
35. Ungermannova D, Gao Y, Liu X. Ubiquitination of p27Kip1 requires physical interaction with cyclin E and probable phosphate recognition by SKP2. J Biol Chem. 2005;280:30301-30309.
36. Matsuo Y MacLeod RA, Uphoff CC, et al. Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia. 1997;11:1469-1477.
37. Walters DK, Stoffregen EP, Heinrich MC, DeiningerMW, Druker BJ. RNAi-induced downregulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. Blood. 2005: 105:2952-2954.
38. Koschmieder S, Hofmann WK, Kunert J, et al. TGF beta-induced SMAD2 phosphorylation predicts inhibition of thymidine incorporation in CD34+ cells from healthy donors, but not from patients with AML after MDS. Leukemia. 2001; 15: 942-949.
39. Carroll M, Tomasson MH, Barker GF, GolubTR, Gilliland DG. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci U S A. 1996;93:14845-14850.
40. Nakayama K, Nagahama H, Minamishima YA, et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J. 2000;19: 2069-2081.
41. Passegue E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U S A. 2003;100 Suppl 1:11842-11849.
42. Deininger MW, Vieira SA, Parada Y, et al. Direct relation between BCR-ABLtyrosine kinase activity and cyclin D2 expression in lymphoblasts. Cancer Res. 2001;61:8005-8013.
43. Komatsu N, Watanabe T, Uchida M, et al. A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells. J Biol Chem. 2003;278:6411-6419.
44. Grimmler M, Wang Y Mund T, et al. Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell. 2007; 128:269-280.
45. Kitajima S, Kudo Y Ogawa I, et al. Role of Cks1 overexpression in oral squamous cell carcinomas: cooperation with Skp2 in promoting p27 degradation. Am J Pathol. 2004;165:2147-2155.
46. Shapira M, Ben-lzhak O, Bishara B, et al. Alterations in the expression of the cell cycle regulatory protein cyclin kinase subunit 1 in colorectal carcinoma. Cancer. 2004;100:1615-1621.
47. Masuda TA, Inoue H, Nishida K, et al. Gyclindependent kinase 1 gene expression is associated with poor prognosis in gastric carcinoma. Clin Cancer Res. 2003;9:5693-5698.
48. Kamura T, Hara T, Matsumoto M, et al. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat Cell Biol. 2004;6: 1229-1235.
49. Matulonis U, Salgia R, Okuda K, Druker B, Griffin JD. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol. 1993;21:1460-1466.
50. Podar K, Mostoslavsky G, Sattler M, et al. Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells. J Biol Chem. 2004;279:21658-21665.
51. Hu Y Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet. 2004;36:423-461.